The Gold Trade, May 24
Health Care: Drugs
OxiGene Inc. (OXGN: NASDAQ)
$3.27 -0.04 | -1.21%
05/24/13 - 03:23 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 3.27 |
| 52 Week High | 11.76 |
| 52 Week Low | 3.10 |
| Avg. Daily Vol. (Mil) | 0.04 |
| Beta (3 year) | 2.30 |
| Share Related Items | |
| Mkt Cap (Mil) | 7.44 |
| Shares Out (Mil) | 2.27 |
| Float (Mil) | 2.16 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.50 |
| Current Ratio | 6.00 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 177.08 |
| Price/Book | 1.71 |
| Price/Cash Flow | -0.80 |
| Per Share Data | |
| Earnings | -5.13 |
| Sales | 0.02 |
| Book Value | 1.91 |
| Cash Flow | -4.32 |
| Business Summary | |
|---|---|
| OxiGene, Inc is a clinical-stage, biopharmaceutical company that develops novel therapeutics to treat cancer and eye diseases. | |
| General Information | |
| 701 Gateway Boulevard
Suite 210 South San Francisc, CA 94080 |
|
| www.oxigene.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 7 | |
| CEO: Dr. Peter J. Langecker,M | |
| Short Interest | |
| Current Month (Mil) | 0.07 |
| Previous Month (Mil) | 0.05 |
| Short Interest Ratio (Days) | 1.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -192.20 |
| Return on Investments | -229.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with OXGN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorSmall-Cap Stocks in Danger ...
- UserMy Portfolio
- UserMy Portfolio
- Contributor5 Drug Stock Losers of 2010
- UserASCO 2010 Part 2
- UserBIN
- UserJBOND Portfolio 1
- UserASCO 2009 Nymph's Watch List.
Latest OXGN Headlines from TheStreet
- OXiGENE Reports First Quarter 2013 Financial Results 05.06.13 | 04:05 pm
- OXiGENE Announces Completion Of Enrollment Of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial 04.24.13 | 04:04 pm
- OXiGENE Announces First Quarter 2013 Earnings Conference Call And Webcast 04.24.13 | 06:04 am
- OXiGENE Announces $5 Million Private Placement 04.11.13 | 08:04 am
- OXiGENE Announces Issuance Of Patent For Benzosuberenes, A Novel Anticancer Class Of Agents 03.20.13 | 04:03 pm
- OXiGENE Reports Full Year 2012 Financial Results 03.12.13 | 04:03 pm
- OXiGENE Announces Year-End 2012 Earnings Conference Call And Webcast 03.04.13 | 02:03 pm
- 5 Stocks Under $10 Ready to Soar Higher 02.07.13 | 01:02 pm
- OXiGENE Announces ZYBRESTAT(R) Plus Avastin(R) Continues To Be Well Tolerated In Second Interim Toxicity Analysis Of A Phase 2 Ovarian Cancer Trial 02.06.13 | 04:02 pm
- 3 Stocks Under $5 Making Big Moves 02.05.13 | 02:02 pm
Press Releases for OXGN
Partner Headlines for OXGN
- OXiGENE Announces Changes to Board of Directors - Benzinga 09.09.11 | 04:09 pm
- Will the Next Apple or Google Be Found Among These Micro Caps? - Seeking Alpha 08.18.11 | 09:08 am
- ZYBRESTAT Results Suggest Improvement in Overall Survival in Phase 2/3 Study in Anaplastic Thyroid Cancer - Benzinga 06.06.11 | 04:06 pm
- Morning Market Movers - Benzinga 06.06.11 | 09:06 am
- 7 Big Movers That Investors Must Watch This Week - Seeking Alpha 06.06.11 | 08:06 am
- ASCO 2011: Opportunities for Biotech Investor Success and Failure - Seeking Alpha 05.02.11 | 09:05 am
- UPDATE 1-Oxigene reports positive data on cancer drug - Reuters 10.11.10 | 08:10 am
- Three Promising Small-Cap Cancer Plays - Seeking Alpha 05.17.10 | 08:05 am
- UPDATE 1-Oxigene says auditors raise going concern doubts - Reuters 03.19.10 | 08:03 am
- UPDATE 1-Oxigene to cut half the jobs, sees Q1 charge - Reuters 02.11.10 | 11:02 am
